What Happened

Joshua Bradley, 30, of Pittsfield, Massachusetts, was charged in federal court in Boston with five counts of acquiring a controlled substance by fraud, deception and subterfuge while working as a licensed pharmacist at a national pharmacy chain.

According to the charging documents, Bradley diverted dextroamphetamine and Adderall intended for customers, taking the stimulants for his own personal use while on the job. The charges allege the drugs were acquired outside any legitimate prescription or dispensing pathway — by fraud, deception and subterfuge rather than through a valid patient order.

The case remains pending. An initial appearance was scheduled for September 9, 2026, and Bradley is presumed innocent unless and until proven guilty.

What Went Wrong

The public record does not describe the pharmacy's internal controls, so the failure analysis below is hypothesis based on the pattern alleged. Self-diversion of stimulants by a staff pharmacist is among the hardest insider threats to detect, and commonly points to gaps such as:

  • Employee dispensing and withdrawal activity not flagged for independent review — a pharmacist can move stock in ways that bypass patient-specific prescriptions.
  • Schedule II inventory not reconciled against dispensing records and physical counts on a frequent basis, allowing shrinkage to accumulate unnoticed.
  • Purchasing records (DEA Form 222 order forms) not reconciled against actual dispensing, so missing product is absorbed into expected variance.
  • No review of discrepancy trends by shift, day of week, or individual employee to surface patterns.
  • Red-flag monitoring applied to patients and prescribers but not to pharmacy staff themselves, who know the count and audit schedules.
  • No separation of duties between ordering, receiving and counting, so the same pharmacist who acquired product could also account for it.

The five-count structure suggests repeated acquisitions over a period of time rather than a single lapse. Each undetected acquisition made the next one easier: nothing in the count or reconciliation cycle forced an explanation, so the behavior could continue until it was discovered by an outside investigation.

How It Could Have Been Prevented

  • Reconcile Schedule II purchases, dispensing and physical inventory at least weekly, investigating any variance before reordering.
  • Require a second pharmacist or technician to witness and document all non-patient-specific withdrawals and returns of controlled substances.
  • Review DEA Form 222 order records against dispensing reports to confirm ordered quantities match legitimate need.
  • Run cycle counts of high-risk stimulants on a randomized schedule so employees cannot predict audit timing.
  • Flag any controlled substance transaction linked to an employee's own profile for manager review, and train all staff on the red flags of diversion.
  • Conduct a documented monthly review of employee-related controlled substance activity and retain the review records.

Related Guidance

Sources